Background {#Sec1}
==========

Indigenous populations worldwide suffer from a high burden of infectious diseases. As with Indigenous populations elsewhere, Indigenous Australians of Central Australia share many of the same issues of remoteness, overcrowding, poverty and poor access to sanitation and health care \[[@CR1]--[@CR3]\].

Skin and soft tissue infections (SSTIs) are observed to be extremely common within the Indigenous population of Central Australia. The combination of socioeconomic disadvantage, high rates of communicable infections such as scabies and non-communicable diseases including diabetes mellitus provide a highly vulnerable host for SSTIs \[[@CR2], [@CR3]\]. *Staphylococcus aureus* infection is responsible for significant morbidity and mortality amongst this population, with SSTIs the leading cause of *S. aureus* bacteraemia \[[@CR4]\] and frequently associated with prolonged hospital admissions for wound care with subsequent community dislocation. Despite this, the burden of disease due to superficial SSTIs in the Central Australian Indigenous population has not previously been investigated.

Community-associated methicillin-resistant *S. aureus* (CA-MRSA) and Panton Valentine leucocidin (PVL) positive infection are prevalent and seemingly on the increase in regional studies on *S. aureus* bacteraemia \[[@CR4]--[@CR7]\]. The rise of this *S. aureus* phenotype may be contributing to the burden of SSTIs related disease \[[@CR8]\]. While the molecular epidemiology of *S. aureus* has been described in Indigenous Australians in tropical northern Australia \[[@CR9]\], data on the circulating *S. aureus* clones associated with SSTIs is lacking for the geographically and ethnically distinct desert regions of Central Australia. Furthermore, the correlates between the molecular epidemiology and clinical characteristics including outcomes of complicated *S. aureus* SSTIs is unknown.

Additionally, the prevalence of a newly defined species, *S. argenteus* \[[@CR10]\] has not been established. This is of interest as *S. argenteus*, formerly known as *S. aureus* CC75, is common in the Indigenous population of tropical northern Australia \[[@CR11]\].

Methods {#Sec2}
=======

Alice Springs Hospital (ASH) is the sole hospital providing tertiary health services for Central Australia, a population of approximately 60, 000 over a catchment area of 1.6 million square kilometers \[[@CR12]\]. The catchment region is predominantly within the Northern Territory but also extends into Western Australia, South Australia and Queensland. Approximately 44% of the population identify as Indigenous but represent over 70% of ASH inpatients.

Data pertaining to the Diagnosis-Related Group (DRG) 'cellulitis, boil, furuncle, carbuncle and abscess' for the calendar year 2014 at ASH was queried to establish the incidence of hospital admissions due to SSTIs \[[@CR13]\]. Australian Bureau of Statistics (ABS) population data \[[@CR14]\] was utilised to calculate the regional incidence of SSTIs. The ABS estimate the total population for the Alice Springs, Barkly, Central Desert and MacDonnell Local Government Areas to be 48, 079 persons, with 20,262 persons identifying as Indigenous and 27,817 persons identifying as non-Indigenous \[[@CR14]\].

We conducted a prospective, observational cohort study of a subset of patients presenting to ASH with a complicated, abscess related SSTI during a 1 month period (October 2014). We identified cases via operating theatre lists and included patients with: (1) spontaneous SSTI due to a carbuncle or furuncle, (2) surgical intervention required, and (3) available *S. aureus* isolate. Exclusion criteria were: (1) secondary infection related to a wound, and (2) polymicrobial infections.

We obtained microbiological cultures from routine clinical specimens, with preference for surgical specimens. *S. aureus* was identified by routine laboratory protocols (morphology, catalase and *Staphaurex* tests (Oxoid, 2011)), with organism confirmation and antimicrobial susceptibility testing performed on the *Vitek 2* (Biomerieux, version 7.01) using the Clinical Laboratory Standards Institute M100-S24 Performance Standards. We used real-time polymerase chain reaction (PCR) to detect the presence of the *nucA*, *mecA* and *lukSF* genes to determine the status of *S. aureus*, methicillin-resistance and PVL respectively. High resolution melting (HRM) analysis in conjunction with real-time PCR was used to discriminate the different clonal complexes \[[@CR15]\]. We used ST93 rather than CC93 for those inferred to be ST93, as ST93 is a singleton sequence type with no identified related sequence types in the MLST database. We defined CA-MRSA as resistant to \<3 non β--lactam antibiotic classes, and multi-resistant MRSA (mMRSA) as resistant to ≥3 non β--lactam antibiotic classes. Clinical data of cases was obtained from ASH medical records and included demographics, co-morbidities, recent hospitalization, infection, treatment and outcome data.

We analyzed differences between clonal types, clinical and outcome data using Analysis of Variance for continuous data and Fisher's exact test for categorical variables in R version 3. 1. 2 (R Development Core Team 2014). Incident rate ratios were calculated in Stata version 14.2 (StataCorp, College Station, Texas).

Ethics approval was granted by the Central Australian Human Research Ethics Committee (HREC-14-223).

Results {#Sec3}
=======

Skin and soft tissue infections represented by the DRG code 'cellulitis, boil, furuncle, carbuncle and abscess' constituted 2.1% of all ASH admissions during 2014. Consistent with previous years, it was the most frequent reason for admission under the General Surgical Unit. Overall, there were 462 ASH admissions attributed to SSTIs with the majority occurring in Indigenous patients (*n* = 382, 82.6%). The estimated incidence of SSTIs within the Indigenous population was 18.9 per 1, 000 people years and within the non-Indigenous population was 2.9 per 1, 000 people years, within an incident rate ratio of 6.6 (95% confidence interval 5.1--8.5).

Forty-nine cases for the prospective, observational cohort study were identified following screening and application of exclusion criteria. Most identified as Indigenous (90%), median age was 30 years and approximately 60% were female (Table [1](#Tab1){ref-type="table"}). Despite the young population age, comorbidities with diabetes mellitus (50%), chronic kidney disease (25%), obesity (27%) and scabies infection (25%) were common. Almost half (49%) the population lived in remote communities.Table 1Correlation of clinical variables and *S. aureus* clonal complexesVariableOverall *n = 49*\
n (%^a^), median (IQR)At least one isolate ST93 *n = 24*\
n (%), median (IQR)At least one isolate CC121 *n = 15*\
n (%), median (IQR)Other clonal complexes *n = 10*\
n (%), median (IQR)Demographics Ethnicity: Indigenous44 (89.8)22 (91.7)14 (93.3)8 (80.0) Gender: Female29 (59.2)12 (50.0)9 (60.0)8 (80.0) Age (years)30.0 \[10.0, 46.0\]28.5 \[11.2, 47.0\]34.0 \[24.5, 45.5\]20.5 \[4.5, 42.2\] Residence  Town camp12 (24.5)6 (25.0)4 (26.7)2 (20.0)  Remote community24 (49.0)12 (50.0)6 (40.0)6 (60.0)  Prison1 (2.0)1 (6.7)  Visitor2 (4.1)1 (4.2)1 (10.0)  House in Alice Springs10 (20.4)5 (20.8)4 (26.7)1 (10.0)Co-morbidities Diabetes mellitus22 (44.9)12 (50.0)6 (40.0)4 (40.0) Chronic kidney disease12 (24.5)6 (25.0)3 (20.0)3 (30.0) Haemodialysis2 (4.1)2 (8.3)0 (0.0)0 (0.0) Excess alcohol use6 (12.2)3 (12.5)2 (13.3)1 (10.0) Obesity (BMI ≥ 30)13 (26.5)3 (12.5)7 (46.7)3 (30.0) Cardiac failure6 (12.2)2 (8.3)3 (20.0)1 (10.0) Ischaemic heart disease4 (8.2)2 (8.3)1 (6.7)1 (10.0) Scabies12 (24.5)5 (20.8)4 (26.7)3 (30.0) Asthma5 (10.2)1 (4.2)1 (6.7)3 (30.0)Healthcare exposure Admission in previous 6 months18 (38.3)9 (39.1)5 (33.3)4 (44.4) Previous CA- MRSA18 (38.3)10 (43.5)3 (20.0)5 (55.6)Clinical presentation Size (cm)4.0 \[3.0, 5.0\]4.0 \[2.5, 5.0\]4.0 \[3.0, 6.0\]5.5 \[3.5, 9.0\] Duration (days)5.0 \[2.0, 7.0\]5.5 \[3.2, 7.0\]4.0 \[2.0, 6.5\]3.0 \[2.0, 7.0\] Site of infection  Head & neck8 (16.3)5 (20.8)3 (20.0)  Upper limb9 (18.4)7 (29.2)1 (6.7)1 (10.0)  Torso6 (12.2)3 (12.5)13.3 (2)  Buttock/groin/thigh12 (24.5)6 (25.0)2 (13.3)1 (10.0)  Lower leg11 (22.4)2 (8.3)26.7 (4)3 (30.0)  Multiple3 (6.1)1 (4.2)13.3 (2)5 (50.0)Treatment Time to surgery (days)1.0 \[1.0, 1.0\]1.0 \[1.0, 1.0\]1.0 \[1.0, 1.0\]1.0 \[1.0, 1.0\] Antimicrobials prior surgery  Inactive18 (36.7)13 (54.2)5 (50.0)  Active30 (61.2)10 (41.7)15 (100.0)5 (50.0) Planned oral antibiotic duration (days)7.0 \[2.0, 7.0\]6.5 \[3.2, 7.0\]5.0 \[0.0, 7.0\]7.0 \[5.5, 7.0\]Clinical outcomes Length of stay (days)3.0 \[2.0, 7.0\]3.0 \[3.0, 6.0\]2.0 \[2.0, 6.5\]3.0 \[2.2, 7.0\] Progression to deep structures5 (11.9)3 (15.0)0 (0.0)2 (25.0) Secondary infection1 (2.5)0 (0.0)1 (7.7)0 (0.0) Return to theatre6 (12.5)6 (26.1)0 (0.0)0 (0.0) Readmission within 30 days4 (8.3)2 (8.7)2 (13.3)0 (0.0) Unscheduled medical review8 (21.1)4 (23.5)2 (15.4)2 (25.0) Repeat antibiotics required10 (26.3)3 (17.6)6 (46.2)1 (12.5)Antimicrobial susceptibility Methicillin resistance28 (57.1)23 (95.8)0 (0.0)5 (50.0) Clindamycin resistance3 (12.5)9 (60.0) Trimethoprim/sulfamethoxazole resistance0 (0.0)0 (0.0)^a^Calculation of percentages takes into account missing data points

All cases had community onset disease, 36.7% had been admitted to ASH in the preceding 6 months and 38% had CA-MRSA previously isolated (clinical or screening specimens). CA-MRSA was the predominant phenotype (57%). Many patients received inactive empirical antimicrobial therapy (36.7%) prior to surgical intervention. The most frequently prescribed empiric antimicrobials were flucloxacillin (50%), vancomycin (20%) and cephazolin (14%). Surgical intervention was generally performed within 1 day of admission. Blood cultures were obtained in 16 cases (33%) and were positive for MSSA in just one instance.

Clonal complex and *pvl* status was successfully determined for 50 isolates from 47 patients. Eight clonal complexes were identified (Table [2](#Tab2){ref-type="table"}). The clonal complexes with the highest frequency were ST93 (48%) and CC121 (30%). Of the paired isolates, one case had two MSSA strain types (CC5 and CC121) and two cases had concurrent MSSA and CA-MRSA strain types (CC5 and CC8, and CC1 and ST93). *pvl* positive disease dominated the cohort with 90% of isolates carrying the *lukSF* gene, occurring in both MSSA and CA-MRSA isolates and across all clonal complexes except for CC1 and CC88. *S. argenteus* was not identified.Table 2*S. aureus* isolates: Frequency of clonal complexes and carriage of *pvl* and mecA genesClonal complex\
n (%)*pvl* positive\
n (%)mecA positive\
n (%)Overall (*n* = 50)45 (90.0)28 (56.0)CC11 (2.0)0 (0)0 (0)CC54 (8.0)3 (75.0)3 (75.0)CC83 (6.0)1 (33.3)1 (33.3)CC221 (2.0)1 (100.0)0 (0)CC301 (2.0)1 (100.0)1 (100.0)ST9324 (48.0)24 (100.0)23 (95.8)CC12115 (30. 0)15 (100.0)0 (0)CC881 (2.0)0 (0)0 (0)

There was clear correlation between clones and antimicrobial phenotype. The majority of ST93 isolates were CA-MRSA (96%), whilst all CC121 isolates were MSSA (*p* \< 0.001). 60% of CC121 isolates were resistant to clindamycin, compared to 12.5% of ST93 isolates being clindamycin resistant (*p* = 0.006). Trimethoprim/ sulfamethoxazole resistance occurred in two *pvl* positive CC5 isolates (4%).

There were some differences between *S. aureus* clones and clinical variables (Table [1](#Tab1){ref-type="table"}). On univariate analysis, infections due to ST93 were more likely to require further debridement (*p* = 0.039) but this group also more frequently received inactive antimicrobial therapy prior to debridement (*p* \< 0.001).

Discussion {#Sec4}
==========

Key findings of this study include the very large burden of SSTIs experienced in Central Australia and the vast disparity between Indigenous and non-Indigenous Australians. The incidence of SSTIs requiring hospitalisation within the Indigenous population of Central Australia is estimated to be 18.8 per 1000 people years. This is almost seven times the incidence for the local non-Indigenous population. More concerning, the incidence is over 30 times the estimated national Australian hospitalisation rate for cutaneous abscesses of 62 per 100, 000 people years \[[@CR16]\]. Moreover the incidence is significantly higher than other developed nations, with an American retrospective survey describing an inpatient admission SSTI incidence of 2.19 per 1, 000 person years \[[@CR8]\].

There continues to be a rise in CA-MRSA particularly within Australian Indigenous communities \[[@CR7]\] and our study reflects this trend. We have demonstrated that CA-MRSA is now the dominant *S. aureus* phenotype in carbuncle and furuncle related SSTIs in the desert regions of Central Australia. The prevalence of CA-MRSA in this SSTI subset (57%) well exceeds the prevalence rates of approximately 20% described in previous Australian *S. aureus* studies \[[@CR6], [@CR7], [@CR17]\]. CA-MRSA is increasingly responsible for SSTIs in Australian Indigenous populations, and in particular the dominant ST93-MRSA clone has continued its spread within Australia into the desert regions of Central Australia. MSSA continues to contribute substantially to the burden of carbuncle and furuncle related SSTIs with CC121 the major MSSA clone. Notably, both ST93 and CC121 are *pvl* positive clones.

Despite the geographic isolation, high Indigenous population and substantial burden of disease, the molecular epidemiology of SSTI isolates in Central Australia had a number of similarities to other Australian regions. Clonal diversity is a unique feature of *S. aureus* in Australia, with a recent prevalence survey identifying more than 30 clones in CA-MRSA alone \[[@CR17]\]. There are six major MRSA clones including ST93-IV, ST30-IV, ST1-IV, ST45-V, ST78-IV and ST5-IV \[[@CR17]\]. ST93 is notable for causing abundant \[[@CR9], [@CR17], [@CR18]\] and possibly more virulent disease in Australia \[[@CR19]\] . We also observed significant clonal diversity with 8 clonal complexes identified within 50 isolates, including CC1, CC5, CC8, CC22, CC30, ST93, CC121 and CC88.

Like other regions in Australia, we observed ST93 to be the most frequent strain (48%) and strongly associated with CA-MRSA (96%). ST93 has been found to hyperexpress the exotoxin α-haemolysin which enhances the virulence of the clone, particularly in SSTIs \[[@CR20]\]. The high virulence and expression of α-haemolysin in ST93 may be a driving factor in the substantial burden of disease seen in Central Australia \[[@CR19]--[@CR21]\].

Following ST93, the next major clone was CC121 (30%), which was exclusively methicillin-susceptible. The association of CC121 with SSTI is consistent with the international literature and CC121 is phenotypically usually MSSA \[[@CR22]\]. The molecular epidemiology of MSSA infections has been studied in less detail than CA-MRSA \[[@CR23]\], but CC121 is commonly associated with SSTIs in Australia. However, the high prevalence of CC121 in our study (30%) is greater than that reported elsewhere in the Northern Territory 'Top End' and metropolitan centers \[[@CR9], [@CR18]\], and may be a unique feature of the Central Australian region.

The absence of *S. argenteus* is an interesting finding of this study and key difference to other Australian regions. *S. argenteus* was initially reported in the Northern Territory 'Top End' \[[@CR9], [@CR24]\], but it is now clear it has a global distribution \[[@CR10]\]. The clinical niche of *S. argenteus* appears to differ from *S. aureus* \[[@CR21]\]. *S. argenteus* may have less of a predilection to cause abscesses and furuncles and further studies of non-complicated SSTI will be required to determine whether *S. argenteus* is truly absent from Central Australia.

The dominance of *pvl* positive *S. aureus* isolates (90%) may be contributing to the very high incidence of abscess related SSTIs in Central Australia \[[@CR9]\] and is notable for two reasons. Firstly, it was widespread in both MSSA and CA-MRSA isolates. The association between PVL and abscess related SSTIs is well described \[[@CR25]\], however the prevalence of *pvl* in our cohort was substantially higher than in other Australian urban settings (MSSA 15%, CA-MRSA 42%) \[[@CR18]\] and the Northern Territory Top End (MSSA 40%, CA-MRSA 54%). Secondly, the presence of *pvl* appears to have limited impact on clinical outcomes following surgical intervention. Controversy continues regarding the pathogenic role of PVL, with laboratory and animal model data suggesting it is not a major virulence factor \[[@CR26], [@CR27]\]. In our study, detailed clinical outcome comparisons were limited by the small number of *pvl* negative cases (10%). Despite this, most patients achieved good clinical outcomes with only one episode of bacteraemia and a minority experiencing progression to deep tissue structures (12%) and secondary infection (2.5%). It was not possible to determine if these complications were related to the presence of *pvl* or a delay in presentation to health-services or poor wound care upon discharge. Therefore, we believe the typical rapid response to surgical intervention observed in our study provides further support to the findings of Shallcross et al. that provided 'appropriate surgical treatment and the correct antibiotics' are received, PVL appears to have little impact on clinical outcomes \[[@CR25]\].

Patients with CA-MRSA frequently received inactive empiric antimicrobial therapy with antibiotic prescription often in accordance with the Australian Therapeutic Guidelines recommendation of di/flucloxacillin for empirical therapy \[[@CR28]\]. It follows then that infections due to ST93 were more likely to receive inactive antimicrobials compared to CC121 related infections (54.2% vs 100%, *p* \< 0.001). More importantly, all cases requiring further debridement (*n* = 6) were ST93 (*p* = 0.039) and 50% of these received inactive empiric antimicrobials. The high rates of CA-MRSA and potential impact on clinical outcomes lead us now to recommend the empiric use of vancomycin for patients in Central Australia presenting with SSTIs requiring surgical management. Trimethoprim-sulfamethoxazole may be a preferred empiric oral agent given the high rates of observed clindamycin resistance (32%) and dosing ease.

Associations between clonal complexes and antibiograms were noteworthy. Clindamycin resistance occurred in 32% of isolates, substantially higher than previous studies \[[@CR17]\]. There was also a significant difference in clindamycin resistance between the major strains CC121 (60%) and ST93 (12.5%), *p* = 0.006. The impact on antimicrobial prescribing is attenuated by CC121 isolates being exclusively MSSA but this highlights the evolution to a more broadly resistance antibiogram. The rise in clindamycin resistance may be driven by high use of macrolide antibiotics in Indigenous communities of Central Australia, typically indicated for *Chlamydia trachomatis* or chronic suppurative lung disease.

There are now reports of resistance to trimethoprim-sulfamethoxazole in CC5 strains from Indigenous communities in the neighboring jurisdiction of Western Australia \[[@CR29]\]. We found two CC5 trimethoprim-sulfamethoxazole resistant MRSA strains that were also *pvl* positive. Therefore, ongoing surveillance for changes in resistance and clonal patterns of *S. aureus* are required to update prescribing recommendations.

This study is limited by its observational design with reliance on coding data to determine SSTI incidence rates and retrieval of clinical data from medical records. It was not possible to obtain ABS population data for the entire ASH catchment given it includes partial Local Government Areas of Western Australia, South Australia and Queensland. Consequently, the population incidence rate may be overestimated. Correlation of the estimated ASH catchment population of 60, 000 with 44% identifying as Indigenous determines an incidence of SSTIs within the Indigenous population as 14.5 per 1, 000 people years and within the non-Indigenous population as 2.4 per 1000 people years.

The small sample size of cases, microbiological isolates and patients with PVL negative disease is the major limitation of this study and prevented detailed molecular and clinical correlations. Similarly, our sampling occurred over 1 month and if seasonal variation was present, we would not have identified this. Review of the geographic distribution of clonal complexes was not possible due to use of broad residential categories and the highly mobile nature of the local Indigenous population. Given asymptomatic patients colonized with *pvl* positive *S. aureus* were not included, associations with *pvl* positivity and clinical disease are only epidemiological in nature and not causal. Other recognized *S. aureus* virulence factors such as α-haemolysin were not assessed.

Conclusions {#Sec5}
===========

In conclusion, we observed extremely high rates of complicated SSTIs requiring hospitalization in Central Australia, with the Indigenous population disproportionately affected. Detailed review of the molecular epidemiology of carbuncle and furuncle related SSTIs revealed the dominance of two clones ST93-MRSA and CC121-MSSA. These two virulent clones both possess the *pvl* gene but the impact of PVL toxin on clinical outcomes remains uncertain. The prevalence of CA-MRSA continues to rise locally, with significant ramifications for antimicrobial prescribing. Empiric intravenous vancomycin or oral trimethoprim-sulfamethoxazole is recommended for this population when antimicrobial therapy is indicated. Prompt surgical intervention remains the cornerstone of treatment. Further studies correlating clonal complex type, asymptomatic *pvl* carriage as well as the presence of other virulence factors will help improve our understanding of the pathogenesis of SSTIs.
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